Article · Safety

Retatrutide side effects: trial data and risks

Retatrutide, an investigational triple-hormone agonist, has shown impressive weight-loss results in clinical trials, but it also produces a predictable set of side effects. Understanding what trials have reported – the most frequent reactions, any serious events, and why products obtained outside a trial carry extra risk – helps South Africans make informed decisions.

What the trials have found

Phase 2 and Phase 3 studies consistently identified gastrointestinal (GI) symptoms as the most common adverse events. Participants reported nausea, diarrhoea, constipation and vomiting, especially during the initial weeks of dose escalation. The symptoms are generally mild to moderate and tend to improve as the body adjusts.

In addition to GI effects, newer trial data have highlighted a neurological sensation known as dysesthesia – unusual tingling or burning sensations on the skin. This was noted in a subset of participants and is considered dose-related.

How often these effects occur

Across the trials, GI side effects were reported by a substantial proportion of participants. Nausea, diarrhoea, constipation and vomiting each appeared in roughly one-third of those receiving the highest study doses, while dysesthesia was observed in a smaller but notable minority.

Serious adverse events

While most reactions were manageable, a minority of participants discontinued the study drug because of adverse events. Discontinuations were reported in the higher-dose arms of the trials, underscoring that the side-effect profile can become a limiting factor for some users.

Why unregistered products add extra risk

Retatrupide is still an investigational medicine. As noted by Drugs.com, it has not been approved by the FDA and is only available to people enrolled in clinical trials; it cannot be legally purchased, prescribed or compounded outside that setting. JoinMidi similarly points out that the drug is not yet approved and can only be accessed through research protocols.

Because the product has not undergone full regulatory review, any version obtained outside a trial has not been evaluated for purity, correct dosing or the presence of contaminants. Without the safeguards that come with approved medicines – such as rigorous manufacturing standards and post-marketing surveillance – users cannot be sure that the product they receive matches the formulation studied in trials. This uncertainty can lead to unexpected or more severe reactions than those documented in the controlled research environment.

Key take-aways for South African readers

  • Common side effects: nausea, diarrhoea, constipation, vomiting and occasional dysesthesia.
  • Frequency: GI events occur in roughly one-third of participants at the highest doses; dysesthesia is less common.
  • Seriousness: a small proportion of trial participants stopped treatment because of adverse events.
  • Risk of unapproved products: without regulatory approval, off-label or grey-market sources cannot guarantee safety, dosing accuracy or product quality.

Anyone considering participation in a retatrutide trial should discuss these potential side effects with a qualified health professional and remain cautious about any product marketed outside the formal clinical-trial framework.

Further reading: Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial (pubmed.ncbi.nlm.nih.gov).

Frequently asked questions

What are the most common side effects of retatrutide?

The most common side effects are gastrointestinal – nausea, diarrhoea, constipation and vomiting – plus occasional dysesthesia, a tingling or burning skin sensation.

How frequently do gastrointestinal side effects occur in the trials?

GI events were reported in roughly one-third of participants receiving the highest study doses.

What is dysesthesia and how often does it appear?

Dysesthesia is an unusual tingling or burning sensation on the skin; it was seen in a smaller but notable minority of trial participants.

Are there any serious adverse events associated with retatrutide?

A small proportion of participants discontinued the study drug because of adverse events, indicating that severe reactions can limit use for some individuals.

Why do unregistered retatrutide products carry extra risk?

Products obtained outside regulated trials have not undergone full regulatory review, so their purity, dosing and contaminant levels are unknown, potentially leading to unexpected or more severe reactions.

Should I talk to a health professional before considering retatrutide?

Yes, anyone thinking about joining a retatrutide trial should discuss the potential side effects with a qualified health professional and remain cautious about any product marketed outside the formal clinical-trial framework.

Sources

  1. alonsomartinmd.com, "Retatrutide Side Effects: What Patients Should Know", 11 September 2026, https://alonsomartinmd.com/blog/retatrutide-side-effects
  2. joinmidi.com, "Retatrutide Side Effects Women Should Know", 8 October 2026, https://www.joinmidi.com/post/retatrutide-side-effects
  3. drugs.com, "Retatrutide: Uses, Dosing, Side Effects, Weight Loss Results - Drugs.com", 30 September 2026, https://www.drugs.com/retatrutide.html
  4. pubmed.ncbi.nlm.nih.gov, "Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial", 2023-08-10, https://pubmed.ncbi.nlm.nih.gov/37366315/